France Next Generation Sequencing Market worth $1.14 billion by 2031
The report "France Next-generation Sequencing Market by Product (Reagents, Kits, Platforms), Service (CHIP Sequencing, Whole Genome, Methyl, RNA Sequencing), Technology (SBS, Nanopore) Workflow (Sequencing, Data Analysis), Application, Competition - Forecast to 2031" is expected to reach USD 1.14 billion by 2031 from USD 0.59 billion in 2026, at a CAGR of 14.2%.
Browse 60 market data Tables and 18 Figures spread through 250 Pages and in-depth TOC on "France Next-generation Sequencing Market by Product (Reagents, Kits, Platforms), Service (CHIP Sequencing, Whole Genome, Methyl, RNA Sequencing), Technology (SBS, Nanopore) Workflow (Sequencing, Data Analysis), Application, Competition - Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/france-next-generation-sequencing-market-241304355.html
The increasing adoption of next-generation sequencing (NGS) in oncology and rare disease diagnostics, along with the implementation of national genomics initiatives such as France Genomic Medicine 2025, is driving the demand for sequencing technologies across hospitals and research institutes in France. Additionally, improvements in sequencing speed, accuracy, and cost efficiency are supporting the broader use of NGS in both clinical and research settings. However, market growth is limited by the high initial investment required for sequencing instruments, laboratory infrastructure, and bioinformatics capabilities.
The sequencing services segment is expected to witness significant growth in the France next-generation sequencing market during the forecast period.
By service type, the France next-generation sequencing market is segmented into sequencing services, presequencing services, bioinformatics & data analysis services, and NGS platform services. Sequencing services are expected to grow substantially during the forecast period, at a projected CAGR of 18.7%. This segment is expected to grow rapidly in the France next-generation sequencing market due to the increasing demand for outsourced sequencing services from hospitals, pharmaceutical companies, and research institutes involved in oncology and genetic disease studies.
The consumables segment is projected to account for a significant share of the France next-generation sequencing market during the forecast period.
By product, the France next-generation sequencing market is segmented into consumables, platforms, and bioinformatics tools. The consumables segment is expected to record the highest CAGR of 13.0%. The recurring nature of consumable purchases makes this segment a substantial contributor to overall market revenue. As sequencing volumes increase across research and clinical applications, the demand for reliable and high-performance consumables continues to grow. The emphasis on quality control and reproducibility in genomic studies drives the adoption of validated consumable products from established manufacturers.
The diagnostics segment accounted for the largest share of the application segment in 2025.
By application, the France next-generation sequencing market is segmented into diagnostics, drug discovery & development, agriculture & animal research, and other applications. In 2025, the diagnostics segment accounted for the largest share of the market. This is attributed to the increasing adoption of next-generation sequencing in France for oncology testing, rare disease diagnosis, and genetic disorder screening.
The report profiles key players such as Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN (Netherlands), Oxford Nanopore Technologies Plc (UK), PacBio (US), and Eurofins Scientific (Luxembourg).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the France Next Generation Sequencing Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
